In keeping with the expectation, c-MET inhibition along with dual Bcl-2/Bcl-xL inhibition causes synthetic lethality in stem-like and established GBM cells, which is pharmacologically exemplified by the drug combination of ABT263 and Crizotinib, two drugs that are tested or used in patients already. Here, BCL2L1 is linked to glioblastoma.